Opinion
- Author:
- Alan P. Lyss, MD
Publish date: March 27, 2020
Dr. Alan P. Lyss reviews data showing that olaparib outperformed chemotherapy in patients with heavily pretreated ovarian cancer.
Opinion
- Author:
- Alan P. Lyss, MD
Publish date: March 26, 2020
Dr. Alan P. Lyss examines how the COVID-19 pandemic has and will affect cancer care and research.
Opinion
- Author:
- Alan P. Lyss, MD
Publish date: March 20, 2020
Dr. Alan P. Lyss reviews a study suggesting that women aged 75 years and older do not benefit from annual mammography.
Opinion
- Author:
- Alan P. Lyss, MD
Publish date: March 13, 2020
Dr. Alan P. Lyss analyzes research showing treatment doesn’t correspond to guidelines in breast cancer patients with deleterious germline mutations...
Opinion
- Author:
- Alan P. Lyss, MD
Publish date: March 6, 2020
Dr. Alan P. Lyss reviews studies of breast cancer patients receiving pembrolizumab in combination with chemotherapy.
Opinion
- Author:
- Alan P. Lyss, MD
Publish date: February 20, 2020
Dr. Alan P. Lyss comments on guidelines for genetic testing in epithelial ovarian cancer and data that support a reexamination of colorectal cancer...
Opinion
- Author:
- Alan P. Lyss, MD
Publish date: February 6, 2020
More evidence is needed before clinicians can rely on these new tools.
Opinion
- Author:
- Alan P. Lyss, MD
Publish date: January 21, 2020
Dr. Alan P. Lyss breaks down how circulating tumor DNA monitoring and the approval of a new targeted agent are both set to change management of pat...
Opinion
- Author:
- Alan P. Lyss, MD
Publish date: December 20, 2019
Dr. Alan P. Lyss explores recent studies on rituximab maintenance in follicular lymphoma and the use of MRI as a supplemental screening for women w...
Opinion
- Author:
- Alan P. Lyss, MD
Publish date: December 6, 2019
Dr. Alan P. Lyss puts some recent FDA approval of crizanlizumab and zanubrutinib into perspective for clinicians.
Opinion
- Author:
- Alan P. Lyss, MD
Publish date: November 22, 2019
Dr. Alan P. Lyss highlights two articles that demonstrate the safety of established treatments – nephrectomy and stereotactic ablative body radioth...
Opinion
- Author:
- Alan P. Lyss, MD
Publish date: November 11, 2019
Dr. Alan P. Lyss reflects on the significance of two studies from ESMO 2019 that show significant survival improvements in NSCLC and breast cancer....
News
- Author:
- Alan P. Lyss, MD
Publish date: October 25, 2019
Dr. Alan P. Lyss breaks down new findings presented at the European Society of Medical Oncology Congress on the expanded use of PARP inhibitors in ...
Opinion
- Author:
- Alan P. Lyss, MD
Publish date: October 11, 2019
Dr. Alan P. Lyss examines the impact of women’s health clinic closures and excessive radiation doses in some lung cancer screening programs.
Opinion
- Author:
- Alan P. Lyss, MD
Publish date: September 30, 2019
Dr. Alan P. Lyss reviews three studies presented at the World Conference on Lung Cancer on the use of tissue biomarkers in predicting the benefit o...
